Pregled bibliografske jedinice broj: 1281207
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients
Baseline IgG-Fc N-glycosylation profile is associated with long-term outcome in a cohort of early inflammatory arthritis patients // ARTHRITIS RESEARCH & THERAPY, 24 (2022), 1; 206, 11 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1281207 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Baseline IgG-Fc N-glycosylation profile is
associated with long-term outcome in a cohort of
early inflammatory arthritis patients
Autori
Senard, Thomas ; Flouri, Irini ; Vuckovic, Frano ; Papadaki, Garyfalia ; Goutakoli, Panagiota ; Banos, Aggelos ; Pucic-Bakovic, Maja ; Pezer, Marija ; Bertsias, George ; Lauc, Gordan ; Sidiropoulos, Prodromos
Izvornik
ARTHRITIS RESEARCH & THERAPY (1478-6354) 24
(2022), 1;
206, 11
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
fragment crystallizable ; immunoglobulin G ; inflammation ; N-glycosylation ; rheumatoid arthritis
Sažetak
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease for which prediction of long- term prognosis from disease's outset is not clinically feasible. The importance of immunoglobulin G (IgG) and its Fc N-glycosylation in inflammation is well-known and studies described its relevance for several autoimmune diseases, including RA. Herein we assessed the association between IgG N-glycoforms and disease prognosis at 2 years in an early inflammatory arthritis cohort. Methods: Sera from 118 patients with early inflammatory arthritis naïve to treatment sampled at baseline were used to obtain IgG Fc glycopeptides, which were then analyzed in a subclass-specific manner by liquid chromatography coupled to mass spectrometry (LC-MS). Patients were prospectively followed and a favorable prognosis at 2 years was assessed by a combined index as remission or low disease activity (DAS28 < 3.2) and normal functionality (HAQ ≤ 0.25) while on treatment with conventional synthetic DMARDs and never used biologic DMARDs. Results: We observed a significant association between high levels of IgG2/3 Fc galactosylation (effect 0.627 and adjusted p value 0.036 for the fully galactosylated glycoform H5N4F1 ; effect -0.551 and adjusted p value 0.04963 for the agalactosylated H3N4F1) and favorable outcome after 2 years of treatment. The inclusion of IgG glycoprofiling in a multivariate analysis to predict the outcome (with HAQ, DAS28, RF, and ACPA included in the model) did not improve the prognostic performance of the model. Conclusion: Pending confirmation of these findings in larger cohorts, IgG glycosylation levels could be used as a prognostic marker in early arthritis, to overcome the limitations of the current prognostic tools.
Izvorni jezik
Engleski
Znanstvena područja
Biologija, Temeljne tehničke znanosti
POVEZANOST RADA
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb,
GENOS d.o.o.
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE